My Legacy Advisors LLC Buys 12,951 Shares of Pfizer Inc. $PFE

Key Points

• My Legacy Advisors LLC increased its position in Pfizer Inc. by 105.1%, now holding 25,278 shares worth $652,000 after acquiring 12,951 additional shares in the last quarter.
• Pfizer reported $14.65 billion in revenue for the latest quarter, outperforming the consensus estimate of $13.43 billion and achieving earnings per share of $0.78.
• The company declared a quarterly dividend of $0.43 per share, equating to an annualized dividend yield of 7.2%, with a payout ratio of 91.49%.

My Legacy Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 105.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,278 shares of the biopharmaceutical company's stock after acquiring an additional 12,951 shares during the quarter. My Legacy Advisors LLC's holdings in Pfizer were worth $652,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Gould Capital LLC raised its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth approximately $27,000. North Capital Inc. purchased a new stake in Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in Pfizer in the 4th quarter worth approximately $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on PFE shares. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Bank of America lifted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Up 0.1%

Shares of PFE traded up $0.02 during mid-day trading on Monday, hitting $24.05. 66,318,769 shares of the company's stock traded hands, compared to its average volume of 45,384,242. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $136.74 billion, a P/E ratio of 12.79, a PEG ratio of 0.78 and a beta of 0.55. The business's 50-day moving average price is $24.63 and its 200-day moving average price is $24.20. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.